INTRODUCTION
Control of cell polarity is essential for the establishment of multicellular tissues in metazoans. Genetic studies in the nematode Caenorhabditis elegans have identified a set of six partition-defective or PAR genes that participate in the polarity program during embryonic development and are conserved in mammals (1) (2) (3) (4) . PAR-1 is required for axis formation in oogenesis and establishment of oocytes in the fruit fly Drosophila melanogaster, both of which are processes associated with microtubule dynamics and stability (5) . Mammals have four PAR-1 orthologs comprising the family of microtubule affinity-regulating kinases (MARKs), which are related to adenosine 5′-monophosphate-activated protein kinase (AMPK). The MARK family comprises four members: PAR-1a (also known as MARK3 or C-TAK), PAR-1b (also known as MARK2 or EMK), PAR-1c (also known as MARK1), and PAR-1d (also known as MARK4 or MARKL1). MARKs regulate cell polarity (3) and trigger microtubule instability by phosphorylating microtubule-associated proteins (MAPs), causing their rapid detachment from microtubules (6, 7) . The best-characterized family member, MARK2, modulates the growth of axonal projections in hippocampal neurons (8) and contributes to the formation of neurites in neuroblastoma cells (9) by phosphorylating the MAP tau (MAPT; also known as TAU). This phosphorylation event modulates microtubule plasticity, which is required for neuronal polarity and the growth of neurites (8, 9) . MARK2 also phosphorylates Rab11 family-interacting protein 2 (FIP2), which regulates lumen polarity (10) and the activity of catenin delta 1 (CTNND1; also known as catenin p120) at the junctional complexes (11) . Loss of function of MARK2, MARK3, or MARK4 in mice leads to metabolic defects, including increased metabolic rate, decreased adiposity, defective gluconeogenesis, and insulin hypersensitivity (12) (13) (14) . MARK2 and MARK3 can compensate for one another during embryogenesis; however, compound homozygous knockout of both is embryonic lethal (12, 15) , whereas loss of three of four alleles causes defects in the development of the glomerular and proximal tubules of the kidneys (16) . All four MARKs are targets of the Helicobacter pylori virulence factor CagA, which disrupts tight junctions and polarity in epithelial cell lines (17) . Other MAPs that are MARK substrates and that direct cell polarity have yet to be identified (18) (19) (20) (21) (22) .
The Ras homolog family member A (RHOA) guanine nucleotide exchange factor ARHGEF2 has been implicated in various cellular processes involving the establishment of cell polarity, including epithelial tight junction formation (23) , proximal tubule paracellular permeability (24) , and endothelial permeability (25) . We have described a RHOAindependent requirement of ARHGEF2 in rat sarcoma-mediated transformation (26) . ARHGEF2 is sequestered in an inhibited state on the microtubule array, where it is tethered by the dynein motor light chain DYNLT1 (27, 28) , and phosphorylated by PAK1 [p21 (RAC1)-activated kinase 1] or PKA (protein kinase A) on the C-terminal negative regulatory site Ser 886 (28, 29) . Phosphorylation at Ser 886 creates a binding site for 14-3-3 proteins, which hold ARHGEF2 in a catalytically inactive configuration (28) . ARHGEF2 can be activated by disassembly of the microtubule array using pharmacologic agents or by the physiologic ligands lysophosphatidic acid and thrombin (30) .
To elucidate the detailed mechanisms by which ARHGEF2 is positively regulated and coupled to the cell polarity program, we sought to systematically determine the ARHGEF2 interaction network using a proteomic approach. We identified MARK3 as a positive regulator of ARHGEF2. MARK3 phosphorylated ARHGEF2 on Ser 151 , which we demonstrated using x-ray crystallographic structure determination, is contained within the DYNLT1-binding region. We showed that the sequence encompassing Ser 151 is conserved across species and is a functional 14-3-3 binding site. When 14-3-3 bound to phospho-Ser 151 , ARHGEF2 was displaced from the dynein motor complex, thereby promoting a catalytically active ARHGEF2 pool that was dissociated from microtubules. Binding of 14-3-3 to phospho-Ser 151 -ARHGEF2 induced its relocalization to the plasma membrane and cytoplasmic compartments, where it activated RHOA to promote the induction of stress fibers and focal adhesions, whereas Ser 151 phosphorylation was antagonized by protein phosphatase 2A (PP2A) phosphatase. We identified ARHGEF2 as a MARK3 substrate activated by a phospho-switch controlling its association with DYNLT1 and showed that this phosphorylation event was required for the formation of polarized spheroid structures.
RESULTS

ARHGEF2 interaction network comprises proteins associated with microtubules or cell division processes
To identify new ARHGEF2 interactors, we used proximity-dependent biotin identification (BioID) (31) by stably expressing Flag-tagged bifunctional ligase-repressor (BirA*) fused to ARHGEF2 in 293 Flp-In T-REx cells, followed by affinity purification and mass spectrometry (MS) (32) . We confirmed six previously known ARHGEF2-interacting proteins, including p21 (RAC1)-activated kinase 4 (PAK4), MARK2, centrosomal protein 170 (CEP170) (33) (34) (35) (36) , and the protein phosphatase 6 catalytic subunit (PPP6C), regulatory subunit 1 (PPP6R1), and the ankyrin repeat domain 28 (ANKRD28) subunit (Fig. 1A, fig. S1A , and table S1) (37) . Gene ontology (GO) analysis and a survey of the literature revealed that many of the ARHGEF2 interactors were associated with (i) microtubule organization and regulation, (ii) vesiclemediated transport (38) , (iii) mitotic cell cycle processes, and (iv) cell polarity (fig. S1B and tables S2 and S3). An ARHGEF2 interactor of particular interest was MARK3 (also known as C-TAK1). MARK3 associates with and phosphorylates cell division cycle 25C (CDC25C) (39) and many other substrates, including protein tyrosine phosphatase H1 (PTPH1), kinase suppressor of Ras1 (KSR1), and plakophilin2 (PKP2) (40) . We further investigated the function of the MARK3-ARHGEF2 complex because these proteins have a common role in promoting microtubule dynamics.
MARK3 interacts with and phosphorylates ARHGEF2 and other MAPs
To understand the potential role of MARK3 and ARHGEF2 signaling networks, we next sought to elucidate the protein interaction network of MARK3. Pyo-tagged MARK3 protein complexes were affinity-purified from 293T cells and identified using MS. Known MARK3 substrates including KSR1 and PTPH1 were detected in this analysis in addition to new MARK3-interacting peptides ( Fig. 1B and table S4 ). Of these, cytoplasmic linker-associated proteins 1 and 2 (CLASP1 and CLASP2) and ARHGEF2 are known microtubule-binding proteins. To confirm the interaction of MARK3 with CLASP1, CLASP2, and ARHGEF2, coimmunoprecipitation assays were performed using constructs expressing Pyo-tagged MARK3 or connector enhancer of kinase suppressor of Ras 1[Pyo-CNK1, a protein scaffold not known to bind to any of the putative MARK3 substrates (41) ]. CLASP1, CLASP2, and ARHGEF2 were detected in immunoprecipitates of MARK3 but not of CNK1 (Fig.   1C ). MARK3 was identified in ARHGEF2 immunoprecipitates from 293T cells, confirming an interaction between the endogenous proteins ( Fig. 1D) . Next, we examined whether these proteins were MARK3 substrates by performing in vitro [g- 32 P]ATP (adenosine 5′-triphosphate) kinase assays with immune complexes. CLASP1, CLASP2, ARHGEF2, or the N-terminal domain of KSR1 was isolated from transfected Cos-7 cells under stringent lysis conditions. MARK3
WT exhibited autokinase activity and phosphorylated the positive control substrate KSR1, whereas MARK3 KD did not. In addition, CLASP1, CLASP2, and ARH-GEF2 were strongly phosphorylated by MARK3
WT but not by MARK3 KD (Fig. 1E ). These data demonstrated that CLASP1, CLASP2, and ARHGEF2 are MARK3 substrates, and all contained MARK3 consensus phosphorylation motifs F a xRxxS*FPxxF a or F a xR/KxxS*xxxF a (where S* is the site phosphorylated, x is any amino acid, F a is a hydrophobic residue with an aliphatic side chain, and F is any hydrophobic amino acid) (40, 42, 43) at sites corresponding to CLASP1 Ser 600 and Ser
1162
, and CLASP2 Ser 370 and ARHGEF2 Ser 151 (Fig. 1F ).
MARK3 phosphorylates ARHGEF2 on Ser 151 and creates a 14-3-3 binding site We mapped the MARK3 binding site on ARHGEF2 using a series of Flag-tagged ARHGEF2 fragments and detected MARK3 only in immunoprecipitates containing the N-terminal portion ARHGEF2. Residues 1 to 243 were necessary for interaction with MARK3, and the addition of the Dbl homology (DH) and pleckstrin homology (PH) domains each contributed to promote maximal binding, although an isolated DH-PH domain failed to bind MARK3 ( Fig. 2A) .
To determine the sites on ARHGEF2 phosphorylated by MARK3, phosphopeptide mapping analysis was performed on the phosphopeptides generated in vitro. The major phosphorylation site was contained within a phosphopeptide that eluted in fractions 37 and 38. Edman degradation and phosphoamino acid analysis revealed that Ser 151 was the residue phosphorylated in this tryptic fragment. When a similar analysis was performed using an ARHGEF2 mutant lacking Ser 151 (ARHGEF2 S151A ), the phosphopeptide eluting in fractions 37 and 38 was nearly abolished (Fig. 2B ). Phosphopeptide analysis of in vivo 32 P-labeled wild-type ARHGEF2 further confirmed that ARHGEF2 Ser 151 was phosphorylated in intact cells (Fig. 2C) .
To validate that ARHGEF2 was a substrate of MARK3, we examined whether MARK3 could phosphorylate ARHGEF2 Ser 151 in vitro if key residues in the MARK3 consensus phosphorylation motif were mutated. On the basis of the radioactivity incorporated into Ser 151 , loss of the hydrophobic residues at positions −5 and +4 and loss of the lysine residue at −3 each severely reduced MARK3 phosphorylation of Ser 151 (Fig. 2D ). These data confirmed that ARHGEF2 is a bona fide substrate of MARK3. Whereas ARHGEF2 orthologs exhibit 67% sequence identity overall ( fig. S2 ), the MARK3 consensus motif residues are completely conserved among vertebrates, including reptiles, amphibians, fishes, and mammals, suggesting an important functional role of this site (Fig. 2E) .
MARK3 phosphorylation of peptide sequences in other substrates frequently creates 14-3-3 binding sites. The ARHGEF2 fragment comprising residues 1 to 243 coimmunoprecipitated with endogenous 14-3-3 ( Fig. 2A) . To characterize the interaction of ARHGEF2 with 14-3-3 in vitro, we analyzed the interaction between recombinant 14-3-3 protein and synthetic fluorescein isothiocyanate (FITC)-labeled peptides containing phospho-Ser 151 and a previously validated 14-3-3 binding motif of ARHGEF2 at phospho-Ser 885 (29 . (A) Left: Flag-tagged ARHGEF2 fragments and wild-type MARK3 were coexpressed in HEK293T cells. Protein complexes were immunoprecipitated, and immunoblots were probed with antibodies specific for MARK3 and pan 14-3-3 to map the interaction. Antibodies recognizing Flag, MARK, and 14-3-3 antibodies were used to detect protein abundance in cell lysates, and a-tubulin was used as a loading control. Right: Schematic representation of the constructs used for mapping the interaction. EV, empty vector; WCL, whole-cell lysates; F.L., full length. (B and C) ARHGEF2 wild-type (top) or mutant ARHGEF2 S151A (bottom) proteins were incubated with [ , and endogenous 14-3-3 using antibodies against MARK3, Flag, and 14-3-3, respectively. Whole-cell lysates were analyzed with the same antibodies to assess protein abundance. Total extracellular signal-regulated kinase (ERK) was used as a loading control (see fig. S3C for quantification). Data are representative of three independent experiments. (E) Myc-tagged wild-type and phosphomimetic mutants S151D and S151E for ARHGEF2 were coexpressed with Flag-tagged DYNLT1. Protein complexes were immunoprecipitated with an antibody recognizing Myc and analyzed by Western blotting. Antibodies against Myc, Flag, and 14-3-3 were used to confirm the amount of ARHGEF2 and to detect DYNLT1 and endogenous 14-3-3 in the complexes, respectively. Protein abundance in whole-cell lysates was analyzed using the same antibodies, and a-tubulin was used as a loading control. Data are representative of three independent experiments. (F) NMR-based GEF assays were performed to measure RHOA exchange rates in the presence of cell lysates from HEK293T cells expressing GFP alone; GFP-ARHGEF2; GFP-ARHGEF2 and Pyo-MARK3; or GFP-ARHGEF2, Pyo-MARK3, and Flag-14-3-3.
The amount of ARHGEF2 in exchange assays was normalized on the basis of GFP fluorescence in the lysate, and protein amounts were detected by Western blotting (inset). The rates were normalized to ARHGEF2 exchange rate. Data are means ± SD of five independent experiments. Statistical significance was determined by a Kruskal-Wallis test with a Dunn's posttest correction for multiple comparisons. *P = 0.0151 (ARHGEF2 compared to ARHGEF2 + MARK3); **P = 0.0072 (ARHGEF2 compared to ARHGEF2 + MARK3 + 14-3-3); **P = 0.0079 (GFP compared to ARHGEF2). NS, not significant. (G) Nucleotide exchange rates for RHOA in the presence of cell lysates from HEK293T cells expressing GFP-ARHGEF2 WT or GFP-tagged ARHGEF2
S151A
. The rates were normalized to ARHGEF2 WT exchange rate. Data are means ± SD of four independent experiments. Statistical significance was determined by a Mann-Whitney test. *P = 0.0286. phospho-Ser 885 ARHGEF2 peptide (K d , 2.3 ± 1.4 mM), both in a phosphorylation-dependent manner (Fig. 3A) .
MARK3 regulates a phosphorylation-dependent switch that controls the localization and activity of ARHGEF2 We have previously mapped the DYNLT1-binding site on ARHGEF2 to residues 139 to 161 (27) . The MARK3 phosphorylation site is located within this DYNLT1-binding site, suggesting that phosphorylation or the subsequent binding of 14-3-3 proteins could potentially disrupt the interaction between DYNLT1 and ARHGEF2. An ARHGEF2 mutant lacking amino acids 87 to 151 no longer binds to DYNLT1 or microtubules and is highly active (27) . Deletion of these residues also diminished the interaction of MARK3 with ARHGEF2, suggesting that the MARK3 binding site overlaps with residues 87 to 151 (Fig. 3B) . Because MARK3 and DYNLT1 bind to a similar region of ARHGEF2, we investigated whether MARK3 affected the interaction between ARHGEF2 and DYNLT1. We observed that increased amounts of MARK3 potently decreased the association of ARHGEF2 with DYNLT1 ( Fig. 3C and fig. S3A ).
We also noted that the amount of 14-3-3 in complex with ARHGEF2 tended to increase with MARK3 expression (Fig. 3C and fig. S3B ) but that MARK3 KD did not directly compete with DYNLT1. These results demonstrated that MARK3 kinase activity was required both to increase the interaction with 14-3-3 and to disrupt the DYNLT1-ARHGEF2 interaction (Fig. 3C) . To probe the requirement of Ser 151 to mediate the MARK3-dependent displacement of DYNLT1, we compared the interaction of DYNLT1 with ARHGEF2
WT or ARHGEF2 S151A in the presence of increasing amounts of MARK3. Increasing MARK3 expression increased 14-3-3 and reduced DYNLT1 bound to wild-type ARHGEF2 but not to the S151A mutant ( S3C ). By contrast, the S885A mutant exhibited less overall interaction with 14-3-3 proteins, consistent with disruption of this known binding site; however, binding of 14-3-3 was increased, whereas DYNLT1 binding was decreased, by MARK3 in the same manner as wild type ( Fig. 3D and fig. S3C ). These data suggested that Ser 151 was phosphorylated by MARK3 to create a 14-3-3 binding site that excluded binding to DYNLT1. In contrast, the C-terminal 14-3-3 binding site centered around Ser 885 had no effect on DYNLT1 interaction with ARHGEF2. To investigate whether the addition of a negative charge on Ser 151 as a result of phosphorylation was sufficient to disrupt the interaction of DYNLT1 with ARHGEF2, we generated two distinct Ser 151 phosphomimetic ARHGEF2 mutants by substituting the negatively charged amino acids aspartic acid (D) or glutamic acid (E) at position 151 and observed no effect on DYNLT1 binding. Both of these mutants exhibited reduced 14-3-3 binding, consistent with the inability of 14-3-3 to bind to phosphomimetic residues ( Fig. 3E) (44, 45) . These results indicate that MARK3 phosphorylation promoted binding of 14-3-3 within the DYNLT1 interaction sequence of ARHGEF2 to disrupt the interaction between the dynein and the guanine exchange factor, potentially affecting the microtubule-tethered inhibited state of ARHGEF2.
To determine how MARK3 might regulate the exchange factor activity of ARHGEF2, we used a real-time nuclear magnetic resonance (NMR)-based assay (27, 46) to measure the exchange activity. MARK3 coexpression with ARHGEF2 increased the rate of RHOA nucleotide exchange, and expression of MARK3 together with 14-3-3 further increased the exchange activity of ARHGEF2 ( Fig. 3F and inset) . Mutation of the MARK3 Ser 151 phosphorylation site on ARHGEF2 decreased its GEF activity (Fig. 3G) . These data support a model that MARK3 regulates a phospho-switch that leads to both the displacement of ARHGEF2 from microtubules and its concomitant activation.
Ser 151 in ARHGEF2 is localized in the core of the DYNLT1-binding groove To investigate whether the phosphorylation of ARHGEF2 on Ser 151 directly controls the interaction between ARHGEF2 and DYNLT1, we measured the binding affinities between a nonphosphorylated FITC-labeled 16-mer peptide derived from ARHGEF2 (residues 142 to 157) or a peptide phosphorylated on Ser 151 to recombinant GST-tagged DYNLT1. Fluorescence polarization assays showed that phosphorylation had no direct impact on binding ( Fig. 4A ; see also Fig. 3E ). The murine ARHGEF2 peptide (residues 133 to 161) interacts with DYNLT1 with low affinity (K d , 80 mM) (27) , resulting in line broadening of the resonances of both the peptide and the protein. This hindered our efforts to determine a high-resolution structure of the DYNLT1-ARHGEF2 complex by NMR and to crystallize the complex.
To capture the bound state of the ARHGEF2 peptide to DYNLT1 for crystallographic and NMR structural studies, we coupled the ARH-GEF2 (residues 136 to 164) peptide to DYNLT1 using a flexible linker to enhance the apparent affinity of the interaction (47) . The binding orientation of the ARHGEF2 peptide was determined using paramagnetic relaxation enhancement experiments using a synthetic ARHGEF2 peptide (ARHGEF2-Cys N-labeled DYNLT1 in the presence of excess unlabeled ARHGEF2 (residues 136 to 161) peptide validated that within the chimera ARHGEF2 bound DYNLT1 in the native manner and saturated the site more fully (Fig. 4B ). Using these spectra to assess native interaction, the linker was progressively shortened (from GLEGGSGGSG to GGSGGSG to G) to remove unnecessary flexible regions. A single glycine linker was sufficient to maintain the native "fingerprint" spectrum, reduce peak broadening, and increase saturation of the binding site. Fifty-two percent of the backbone resonances of this chimera were assigned. Whereas the apo form of murine DYNLT1 did not produce crystals despite extensive screening (~600 unique crystallization conditions), the chimera was readily crystallized in numerous conditions that were further optimized to generate a crystal that diffracted to high resolution.
The crystal structure of the chimera had three molecules per asymmetric unit, two of which formed a homodimer, whereas the third formed a dimer with a symmetrically related molecule ( fig. S4C and table S5). Similar to previously determined DYNLT1 homolog structures, each subunit had two a helices that flanked a central b sheet consisting of four strands (b2′, b1, b4, and b3), one of which (b2) was domainswapped from the other subunit (Fig. 4C) . Because of the absence of electron density, residues 1 to 4 and 73 to 76 of DYNLT1 and residues 136 to 138 and 156 to 164 of ARHGEF2 were not built into the model. ARHGEF2 residues 140 to 155 lay in the grooves formed at the interface of the two homodimeric DYNLT1 subunits. Residues 140 to 144 formed one turn of 3 10 helix, whereas residues 145 to 147 and 153 to 155 had b-strand characteristics with nine backbone hydrogen bonds formed between this stretch of the ARHGEF2 peptide (residues 145 to 155) and DYNLT1 (Fig. 4D ). An H-bond between ARHGEF2 Ala 147 and DYNLT1 Cys 83 was consistent with nuclear Overhauser effects (NOEs) observed between these residues in solution ( fig. S4D ). ARHGEF2 bound to the edge of the b sandwich, extending the domain-swapped antiparallel b sheet of DYNLT1 (Fig. 4C ). Relative to a perfect b strand, ARHGEF2 contained two extra amino acids, which were accommodated in the binding site through a distortion of the b strand (an antiparallel b bulge comprising two type IV b turns) ( Ser 145 was in the core of the DYNLT1-binding site (Fig. 4E) , providing a clear structural basis for the observed competition between DYNLT1 and 14-3-3 for interaction with ARHGEF2. The side-chain hydroxyl of Ser 151 was closely packed and formed hydrogen bonds with the hydroxyls of DYNLT1 Thr 94 and Ser 107 (fig. S4E) ; thus, Ser 151 phosphorylation would introduce a steric clash in this conformation. However, because our in vitro and in vivo observations indicated that phosphorylation alone or phosphomimetic mutations do not disrupt this complex, we propose that flexibility of the b bulge may allow these residues to adopt an alternate conformation in which a phosphorylated Ser 151 side chain can be accommodated in the binding groove. Several structural observations suggested that the b bulge exhibits some conformational dynamics. Besides the hydrogen bonds mediated by the Ser 151 hydroxyl, which would be disrupted upon phosphorylation, and a few bound water molecules, there were few interactions stabilizing the b bulge. Thus, its conformation diverged slightly among each of the three molecules in the asymmetric unit. In NMR experiments, a stretch of four ARHGEF2 amino acids (Leu 144 to Ala 147 ) in the chimera were assigned; however, broadening of resonances from the b-bulge residues was consistent with the presence of multiple interconverting conformations. Further, phosphorylation of DYNLT1 Thr 94 or phosphomimetic mutation (T94E) disrupts its interaction with dynein intermediate chain (DIC) (50) , which lacks the b bulge at this site (51), but DYNLT1 T94E retains binding to ARHGEF2 (27) . The DYNLT1-binding region of ARHGEF2 is remarkably rich in phosphorylation sites (Ser ) that have been reported in previous proteomics studies (33, 35, (52) (53) (54) (55) (56) and could potentially modulate this interaction. The modest affinity of DYNLT1 for monomeric ARHGEF2 peptide would allow kinases to gain access to their phosphorylation motifs, whereas the tethering of ARHGEF2 to microtubules is likely enhanced by avidity in multivalent protein complexes (57) . A structure of mammalian DYNLT1 in complex with the DIC polypeptide (58) has also been determined using this chimeric approach (59).
PP2A and MARK3 regulate the phosphorylation of Ser 151 in ARHGEF2
The PP2A phosphatase promotes mitogen-activated protein kinase (MAPK) signaling by mediating the dephosphorylation of critical 14-3-3 binding sites in KSR1 that are phosphorylated by MARK3 (60) and is also the major phosphatase for different MAPs (61, 62) . Treatment of cells with a low dose of okadaic acid (OA), an inhibitor of PP2A family phosphatases, resulted in an increase in ARHGEF2 Ser 151 phosphorylation as assessed by phospho-Ser
151
-specific antibodies ( fig. S5A ), suggesting that PP2A or a related phosphatase dephosphorylated this residue (Fig. 5A) . Because ARHGEF2 Ser 151 has been identified in a high-throughput screen as a substrate of AMPK (56), we also treated the cells with the AMPK activator 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR), but no apparent change in the phosphorylation of this residue was observed (Fig. 5A) .
To verify whether PP2A modulated regulatory phosphosites on ARHGEF2, we overexpressed the serine-threonine PP2A 56-kDa regulatory subunit b isoform (PPP2R5B), a member of the B′ regulatory subunit of PP2A that specifically interacts with and modulates ARH-GEF2 (26, 30) , in HEK293T cells and observed that both Ser 151 and Ser 885 were efficiently dephosphorylated (Fig. 5B) . We also used tetracyclineinducible (TETi) cell lines expressing Flag-tagged catalytic PPP2CB and regulatory PPP2R5B subunits of PP2A in the presence of MARK3 WT (Fig. 5E ).
MARK3-mediated phosphorylation of ARHGEF2 triggers its redistribution from microtubules to the cytoplasm Binding of 14-3-3 proteins to the MARK3 phosphorylated substrates KSR-1, CDC25C, and PKP2 is associated with alteration in their subcellular localization (40, 72, 73) . We tested whether the phosphorylation of Ser 151 altered the localization of ARHGEF2. Confocal microscopy of transfected HEK293T cells revealed that GFP-tagged wild-type ARHGEF2 (GFP-ARHGEF2 WT ) was localized to microtubule-like filamentous structures, as previously described (Fig. 6, A and B) (27, 28) . MARK3 coexpression disrupted the filament-like localization of GFP-ARHGEF2 WT , inducing a diffuse and uniform cytoplasmic distribution. In contrast, GFP-ARHGEF2 S151A was strongly associated with microtubule-like filamentous structures with some bundling, which was resistant to coexpression of MARK3 (Fig. 6, A and B) .
To determine the requirement of MARK3 in determining the subcellular localization of ARHGEF2, we overexpressed ARHGEF2 WT or ARHGEF2 S151A at low amounts under the control of a TETi promoter in MDCKII cells (pLVX-GFP ARHGEF2
WT or pLVX-GFP ARHGEF2 S151A , respectively) ( fig. S6, A and B) . We observed a diffused distribution of GFP-ARHGEF2 WT (Fig. 6C) . After knockdown of MARK3 using siRNA ( fig. S6C) , we observed that a larger fraction of GFP-ARHGEF2 WT was associated with microtubule-like filamentous structures in the absence of MARK3 and tended to phenocopy the subcellular filament-like distribution of GFP-ARHGEF2 S151A (Fig. 6, C and D) . These data demonstrate that MARK3-dependent phosphorylation of ARHGEF2 promoted its dissociation from the filamentous structures in the cell.
Phosphorylation of ARHGEF2 on Ser
151 by MARK3 promotes stress fibers and focal adhesion formation ARHGEF2 overexpression promotes RHOA activation and induces the formation of stress fibers and focal adhesions (27) . We examined the , and pLVX-GFP ARHGEF2 S151A exposed to increasing amounts of doxycycline (Dox) at 6 and 18 hours. Bottom: Comparison of the wounds at 18 hours. Blue, mask of the original wound; orange, wound not closed. Data are means ± SD of three independent experiments done in triplicates. Statistical significance was determined by a two-way ANOVA test with a Bonferroni posttest correction for multiple comparisons. *P = 0.0445; **P = 0.0029; ****P ≤ 0.0001. NT, no treatment. . This creates a 14-3-3 binding site that disrupts ARHGEF2 interaction with DYNLT1 and releases it from microtubules to activate RHOA and trigger the formation of stress fibers and focal adhesions. MARK3-mediated phosphorylation of Ser 151 is required for epithelial cell polarity in 3D growth. PP2A dephosphorylates Ser 151 through interactions with the B′ subunits. GDP, guanosine diphosphate; GTP, guanosine triphosphate.
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cellular effect of ARHGEF2 using the TETi system to titrate the concentrations of MARK3, ARHGEF2
WT , and ARHGEF2 S151A ( fig. S6 , A, D, and E). After induction with doxycycline, the cells were fixed and stained for vinculin and actin to assess the formation of focal adhesions and stress fibers, respectively (Fig. 7, A to D, and fig. S7 ). Induction of pLVX-GFP-ARHGEF2
WT strongly enhanced the formation of stress fibers and focal adhesions and led to a decreased rate in wound closure, likely due to enhanced adherence of the cells (Fig. 7, A to E, and fig. S7A ). In contrast, the induction of pLVX-GFP-ARHGEF2 S151A produced significantly less stress fibers and focal adhesions and had little impact on wound healing rates compared to that of pLVX-GFP-ARHGEF2 WT (Fig. 7, A to E). The ability of ARHGEF2 to induce actin reorganization and focal adhesion formation was attenuated by silencing of MARK3 with specific siRNA (Fig. 7, A to D) . Consistent with these observations, induced expression of MARK3 promoted the formation of focal adhesions and stress fibers in a manner similar to ARHGEF2 (fig. S7, B to F) . These data demonstrated a functional link between ARHGEF2 and MARK3 and showed that the ability of ARHGEF2 to induce polymerized actin structures was contingent on MARK3.
Phosphorylation of ARHGEF2 on Ser
151 controls cell polarity To determine the role of Ser 151 phosphorylation in cell polarity, we grew transfected cells in three-dimensional (3D) culture. Cells expressing GFP alone initiated lumen formation at day 4, whereas those expressing GFP-ARHGEF2
WT had already established a well-defined lumen. In distinction, the pLVX-GFP-ARHGEF2 S151A cells failed to initiate the formation of proper 3D structures at day 4 ( fig. S8A ). After 8 days of growth in Matrigel, the pLVX-GFP control cells developed a spherical structure with a hollow lumen. Expression of GFP-ARHGEF2 WT led to larger spheroid structures with maintained polarity but with decreased luminal clearance of cells (Fig. 8, A and B) . In contrast, expression of GFP-ARHGEF2 S151A led to smaller spheroids with disorganized arrangement of cells, which were unable to form polarized structures with well-defined lumen (Fig. 8, A and B) .
Analysis of the distribution of the tight junction proteins zonula occludens 1 [ZO-1; also known as tight junction protein 1 (TJP1)] and ZO-2 (or TJP2) in 2D cultures revealed differences in the distribution of ZO-1 and ZO-2 between the control pLVX-GFP cells compared to that of the mutant pLVX-GFP-ARHGEF2 S151A ( fig. S8B ). The staining of ZO-1 and ZO-2 observed along cell junctions in control cells was disrupted in cells expressing GFP-ARHGEF2 S151A , particularly between adjacent cells, consistent with defective tight junction formation. On the other hand, GFP-ARHGEF2 WT -expressing cells showed an enhanced ZO-1 and ZO-2 signal at cell junctions compared to the control GFP ( fig. S8B) .
In 3D cultured cells, we observed a classical distribution of ZO-1 in the lumen of pLVX-GFP cells. This signal was strongly enhanced in pLVX-GFP-ARHGEF2
WT cells with an atypical distribution of the ZO-1 staining at the lumen and the periphery of the spheroid. In contrast, the ZO-1 signal in pLVX-GFP-ARHGEF2 S151A cells was attenuated ( fig. S8C ). These observations reinforce our claim that expression of ARHGEF2 S151A disturbs the normal sequence of cellular polarization required for epithelial cyst formation in 3D culture.
Multiple mitotic figures were evident in the polarized epithelial layer of the spheres in pLVX-GFP-ARHGEF2
WT cells, suggesting enhanced mitosis (Fig. 8C) . We observed enhanced proliferation in spheroids formed by pLVX-GFP-ARHGEF2
WT cells (Ki67 staining), with some luminal cells positive for Ki67 (fig. S8D ). Active caspase 3 was detected in subsets of those luminal cells ( fig. S8E) , showing that these cells were also undergoing cell death processes as well as proliferation.
These data demonstrate that ARHGEF2 contributed to spheroid size and the maintenance of epithelial polarity, whereas a mutant form of ARHGEF2 uncoupled from MARK3 interfered with the signaling program required to establish epithelial polarity and normal spheroid formation.
DISCUSSION
We used a proteomic approach to identify ARHGEF2 as a substrate of MARK3 and mapped a MARK3 phosphosite on Ser 151 of ARHGEF2, which regulates the interaction of ARHGEF2 with the dynein motor light chain DYNLT1 through the creation of a 14-3-3 binding site. We solved a crystal structure of DYNLT1 in complex with an ARHGEF2 peptide comprising the binding site, which reveals that ARHGEF2 residues 140 to 155 lie in the groove formed at the interface of the two homodimeric DYNLT1 subunits. We showed that the phosphorylation of the Ser 151 site per se was insufficient to disrupt this complex. Rather, phosphorylation of Ser 151 created a higher-affinity 14-3-3 binding site, which antagonized ARHGEF2 binding to DYNLT1 through direct competition for the binding site. 14-3-3 proteins frequently regulate the intracellular localization of their target proteins by the masking of subcellular targeting sequences such as nuclear localization sequences. Occluding the binding site between a dynein (DYNLT1) and its cargo protein (ARHGEF2) represents a previously unknown mechanism of regulation of protein subcellular localization by 14-3-3 proteins (45, 74, 75) . We also showed that PP2A restored the dephosphorylated state of Ser 151 and thus returned it to the inactive state associated with the microtubule array. Consistent with this model, stress fiber formation is increased upon inhibition of PP2A family phosphatases with OA (76), which may be mediated through inhibition of ARHGEF2 dephosphorylation. Thus, phosphorylation of Ser 151 served as a reversible switch leading to the displacement and activation of ARHGEF2 from the microtubuleassociated dynein motor complex, and subsequent activation of RHOA, which affected 3D cell growth (Fig. 8D) .
The release from microtubules and activation of ARHGEF2 can thus be regulated by three distinct modes. First, direct disruption of polymerized microtubules by pharmacologic agents such as nocodazole or colchicine releases ARHGEF2 and leads to potent activation of RHOA, an effect that can be reversed by the microtubule-stabilizing drug paclitaxel (27, (77) (78) (79) . Second, the G protein (heterotrimeric guanine nucleotidebinding protein)-coupled receptor (GPCR) ligands lysophosphatidic acid and thrombin trigger activation of ARHGEF2 through the disassembly of the ARHGEF2-dynein multiprotein complex by the concerted action of Ga and Gbg. Ga binds directly to ARHGEF2 and displaces it from DYNLT1, while Gbg binds to DYNLT1 and disrupts its interaction with the DIC, resulting in the release of ARHGEF2 from microtubules (30) . Third, we showed here that the phosphorylation of the Ser 151 regulatory site on the N terminus of ARHGEF2 by MARK3 disrupted its binding to DYNLT1 by creating a 14-3-3 binding site, triggering its release from the microtubule network and activation.
The identification of MARK3 as a kinase, which creates a 14-3-3 binding site on ARHGEF2, is consistent with a more general function of MARK family members in controlling substrate function or activity through the creation of 14-3-3 binding sites (40, 65, 72, 73) . The cell cycle-regulated phosphatase CDC25C is sequestered in the cytoplasm by MARK3-dependent phosphorylation and subsequent binding to 14-3-3. Similarly, phosphorylation of KSR1 by MARK3 creates a 14-3-3 binding site, which impairs its ability to translocate to the plasma membrane and fully activate the MAPK pathway.
S C I E N C E S I G N A L I N G | R E S E A R C H A R T I C L E
ARHGEF2 can be stabilized in an active state when 14-3-3 is bound to phospho-Ser 151 in the N terminus or in an inactive state associated with polymerized microtubules when 14-3-3 is bound to phosphoSer 885 in the C terminus. Similarly, RAF1 can be locked in an active or an inactive state by 14-3-3 binding to distinct C-or N-terminal sites, respectively. PP2A can also activate or inactivate RAF1 by differential dephosphorylation of these regulatory sites (80, 81).
14-3-3 proteins recognize sites containing phosphorylated serine or threonine residues in the context of peptide sequences containing RSx (pS/pT)xP (mode I), RxF/Yx(pS/pT)xP (mode II) (45, (82) (83) (84) , or phosphosites at the penultimate C-terminal position [x(pS/pT)x-COOH] (82, 83, 85) , as well as various noncanonical motifs. We suggest that the ARHGEF2 Ser 885 phosphosite contained within the sequence RRRpSLP is a high-affinity 14-3-3 binding site that conforms to the mode I motif, whereas the Ser 151 phosphosite contained within the sequence KSVpSTT is a lower-affinity suboptimal mode I sequence (http:// scansite3.mit.edu/) (86) because it lacks the Pro residue that directs the C terminus of the peptide out of the binding cleft. A similar site that lacks proline at position +2 and has a lysine at position −3 instead of arginine was identified in the cytoplasmic tail of b 2 integrin, where phosphorylation of threonine within the sequence KSApTTT creates a binding site for 14-3-3, which competes with and displaces talin (87) .
Further work will be required to understand the physiologic input that controls MARK3 activation. The MARK family of kinases includes four family members that regulate the cell cycle and cell polarity, and in turn, these kinases are phosphorylated and activated by LKB1 and aPKC (atypical protein kinase C) (15, 63, 88) . MARK3 is constitutively active in cells (89) , and how its kinase activity is regulated is not currently known. MARK3 is a multiply phosphorylated protein containing at least 17 phosphorylation sites identified in cells. Five MARK3 phosphorylation sites are followed by a proline residue, suggesting that they may be phosphorylated by proline-directed kinases, such as the MAPKs, CDKs (cyclin-dependent protein kinases), or GSK3 (glycogen synthase kinase 3) (65, 90, 91) . Some of these sites represent 14-3-3 binding sites that may control the subcellular localization of MARK3, which is localized in the cytoplasm when phosphorylated and bound to 14-3-3, whereas a MARK3 mutant lacking all 17 known phosphorylation sites and unable to bind to 14-3-3 is enriched on the plasma membrane (65) . The mechanism by which LKB1 activates MARK3 remains unknown. Both MARK2 and MARK3 maintain some activity in LKB1 −/− mouse embryonic fibroblasts and LKB1-null HeLa cells (63) , suggesting that other kinases may activate MARKs and contribute to the basal Ser 151 phosphorylation observed in LKB1-deficient A549 cells. Nevertheless, we have provided genetic and biochemical evidence that LKB1 stimulated ARHGEF2 Ser 151 phosphorylation by MARK3. Further work is required to determine how cell polarization affects the distribution and stoichiometry of MARK3 phosphorylation sites.
ARHGEF2 can interact with all four members of the MARK family and form a complex with the H. pylori bacterial oncoprotein CagA (92) . MARK2 phosphorylates ARHGEF2 on Ser 885 and Ser
959
, leading to the inhibition of the GEF activity with suppression of RHOA activation and stress fiber formation (36) . MAPs MAP2, MAP4, and MAPT/TAU are substrates of MARKs (93) (94) (95) , with an emerging role for MARK4 in the phosphorylation of MAPT/TAU in Alzheimer's disease (96) . The identification of ARHGEF2 and other MAPs including CLASPs, which are involved in planar cell polarity in Arabidopsis thaliana by mediating the orientation of cell division planes in roots (97), as MARK3 substrates suggests that MARK3 is part of a protein network that regulates microtubule function and highlights the importance of the microtubule network in cell polarity. ARHGEF2 may be distinct from other MARK3 substrates linked to cell polarity in that the mutation of a single phosphosite leads to profound defects in 3D growth. Our results reflect the importance of the phosphorylation of Ser 151 in ARHGEF2 in controlling cell polarity in 3D growth in mammalian cells and are consistent with previous observations in which the lack of ARHGEF2 in Xenopus leads to severe defects in neuronal tube closure due to defects in polarity linked with alterations in myosin II light chain phosphorylation and accumulation of Rab11 and actin (98) . ARHGEF2 interacts with ZO-2 in MDCK cells, and the lack of ZO-2 leads to an increase in RHOA activation mediated by ARHGEF2. The lack of ZO-2 also causes misorientation of the mitotic spindle and promotes the formation of multiple lumens in cysts in 3D culture, effects associated with RHOA and CDC42 activation (99) .
Within this MARK3 interaction network, we also identified the PP2A regulatory subunit B alpha (PPP2R2A) and the scaffold subunit A alpha (PPP2R1A) as well as several tyrosine protein phosphatases (PTPN3, PTPN13, and PTPN14) that could influence microtubule dynamics in highly polarized epithelial cells. Because other members of the MARK family interact with ARHGEF2, we cannot exclude the possibility that they could also contribute to the regulation of cell polarity through ARHGEF2 (92) .
ARHGEF2 is a multifunctional guanine exchange factor involved in RHOA activation and MAPK pathway activation through its noncatalytic scaffold function. We have uncovered a previously unknown phosphoregulatory switch, which regulates the subcellular localization and activity of ARHGEF2. The LKB1-MARK3 pathway and PP2A dynamically control the phosphorylation state of ARHGEF2 required for the establishment of cell polarity.
MATERIALS AND METHODS
Cell lines and cell culture All cell lines were maintained in a 5% CO 2 environment at 37°C and grown in Dulbecco's modified Eagle's medium (DMEM; Invitrogen), supplemented with regular or tetracycline-free 10% fetal bovine serum (FBS) (WISENT Inc.) for the doxycycline-inducible cell lines. The following cell lines were used in this study: HEK293T (American Type Culture Collection), Cos cells; MDCKII (S. Muthuswamy, Beth Israel Deaconess Medical Center/Harvard Medical); and 293T-Rex cells expressing Flag-tagged PP2A and PP6 subunits and Flag-tagged GFP. Untransfected 293 Flp-In T-REx cells (Invitrogen) were additionally supplemented with zeocin (100 mg/ml) and blasticidin (5 mg/ml). After transfection and selection of stable lines expressing FlagBirA* alone or FlagBirA*-ARHGEF2, the cells were maintained with hygromycin B (100 mg/ml) according to the manufacturer's instructions.
Transfection
Plasmid DNAs were transfected into HEK293T and 293T-Rex cells using LipoD293 (SignaGen) according to the manufacturer's instructions. Transfected cells were kept for 24 to 48 hours in fully supplemented medium.
3D culture
An eight-well chambered cover glass system (Nunc Lab-Tek II, Thermo Fisher Scientific) was coated evenly with 50 ml of Matrigel matrix (Corning) per well and incubated at 37°C for 40 min to allow the matrix to solidify. MDCKII cells were trypsinized and counted, and a total of 5 × 10 3 cells were resuspended in 400 ml of 3D culture medium [DMEM + 10% FBS + 2% Matrigel ± doxycycline (1 mg/ml)] and placed on top of the solidified matrix. The cells were allowed to grow for 4 or 8 days, with fresh 3D culture medium replenishment every 4 days.
Live imaging HEK293T cells were seeded onto 24-well microplates (ibiTreat, Ibidi). Subconfluent cells were transfected as previously indicated, with pEGFP-C1 or pcDNA3 monomeric Cherry-tagged vectors. After 24 hours of transfection, live-cell imaging of HEK293T was performed on an inverted confocal microscope (Olympus IX81 inverted microscope) with a built-in incubator maintained in a 5% CO 2 environment at 37°C using a 60×/1.2 U-PlanApo water objective (Nikon) and FluoView software (Olympus).
GO, network, motif scan, and ARHGEF2 ortholog analysis GO analysis of the network (100, 101) was performed using all the interactors (http://geneontology.org). A further analysis, using the GO curated terms and literature reports, was done to manually classify six genes that remained unclassified (ANKRD52, ANKRD28, CEP170, CEP170B, PPP6R2, and MTUS1). The final network was built with Cytoscape_v3.1.0 (102) using shared interactions based on GeneMANIA (www.genemania.org/) (103) . The motif scan was done using ScanProsite (http://prosite.expasy.org/scanprosite) (104, 105) submitting the sequences of CLASP1 (Q7Z460), CLASP1 (O75122), and ARHGEF2 (Q92974) according to their UniProt Knowledgebase (UniProtKB) accession entries. ARHGEF2 orthologs were obtained using UniProtKB (www.uniprot.org) (106) , and reviewed (marked with an asterisk in Fig. 2E ) and unreviewed orthologs were selected for the analysis. The UniProtKB sequences were aligned using PRALINE (PRofile ALIgNEment) (www.ibi.vu.nl/programs/pralinewww/) (107, 108).
Immunoblots and coimmunoprecipitation assays
Cells were lysed in NP-40 lysis buffer as previously described (73) to analyze interactions with MARK3. Triton X-100 lysis buffer (50 mM Hepes, 150 mM NaCl, 1% Triton X-100, 10% glycerol, 1 mM EGTA, 1 mM EDTA, and protease and phosphatase inhibitors; Thermo Fisher Scientific) was used to analyze interactions with PP2A and PP6 subunits. After the indicated treatment or transfection, the cells were washed once in cold phosphate-buffered saline (PBS) and lysed for 20 min on ice. After centrifugation at 13,000 rpm for 10 min at 4°C, cleared lysates were directly resolved by SDS-PAGE by boiling in Laemmli sample buffer for 5 min and analyzed by Western blotting or the protein complexes were incubated with antibodies overnight to immunoprecipitate endogenous proteins for 1 hour at 4°C with anti-Flag M2 affinity gel to immunoprecipitate Flag-tagged proteins or an antibody against GFP. After the incubation period, protein A-agarose (Roche) for GFP immunoprecipitates or protein G agarose (BioShop) for endogenous immunoprecipitates was added, and the mixture was incubated for an additional hour at 4°C. The beads were pelleted and washed three times with cold lysis buffer. Samples were processed for SDS-PAGE by boiling in 2× Laemmli sample buffer and analyzed by Western blotting. Quantifications were performed using the ImageJ 1.37c software and were representative of three independent experiments unless indicated otherwise.
Immune complex kinase assays Plasmid DNAs encoding hemagglutinin (HA)-tagged CLASP1, CLASP2, or ARHGEF2 were transfected into Cos cells using the FuGENE reagent (Roche). Forty-eight hours after transfection, Cos cells were lysed under stringent conditions using radioimmunoprecipitation assay (RIPA) buffer (NP-40 lysis buffer containing 0.5% sodium deoxycholate and 0.1% SDS). HA-tagged CLASP1, CLASP2, or ARHGEF2 proteins were immunoprecipitated from cell lysates, following which the immune complexes were washed three times with NP-40 lysis buffer and once with 30 mM tris (pH 7.4). The complexes were then resuspended in 40 ml of kinase buffer [30 Phosphorylation site mapping 32 P-labeled proteins were eluted from the SDS-PAGE gel matrix, precipitated using trichloroacetic acid, and digested with trypsin. An aliquot of the digested protein was adjusted to pH 2 with 20% trifluoroacetic acid and loaded onto a Waters 3.9 mm by 300 mm C 18 column. Reversed-phase HPLC was performed in an LKB chromatography system with two 2150 HPLC pumps, a 2152 LC controller, and a 2140 rapid spectral detector. When buffer salts began to elute, an increasing gradient of acetonitrile in 0.05% aqueous trifluoroacetic acid was added to the column. The stepwise gradient at a flow rate of 1 ml/min was 0 to 40% CH 3 CN for 60 min, 40% CH 3 CN for 10 min, 40 to 60% CH 3 CN for 10 min, and 60% CH 3 CN for 10 min. Fractions were collected at 1-min intervals, and 32 P content was determined by measuring Cerenkov counts. HPLC fractions containing peaks of radioactivity were subjected to phosphoamino analysis and semiautomated Edman degradation in a spinning-cup sequenator, as previously described (109) .
Generation of stable TETi cell lines Stable cells expressing GFP, MARK3, ARHGEF2, GFP-tagged ARHGEF2
WT , and GFP-tagged ARHGEF2 S151A under the control of a TETi promoter were generated using the lentiviral Tet-On 3G Inducible Expression System (Clontech). Lentiviral particles were generated in HEK293T by cotransfection of the viral vectors with packaging and envelope plasmids (pPAX2 and VSV-g) using X-tremeGENE as previously described (26) . Stable doxycycline-inducible MDCKII cells were established by cotransduction with two lentiviral vectors according to the manufacturer's instructions (Clontech): a regulator vector that stably expresses the Tet-On 3G transactivator protein and a second vector that contains the TRE3G promoter controlling the expression of untagged MARK3 or ARHGEF2 in a 1:1 ratio (see fig. S6A for details). The cells were selected with puromycin (10 mg/ml; BioShop) and G418 (200 mg/ml; BioShop) and maintained in DMEM + 10% FBS (tetracycline-free; WISENT Inc.) after antibiotic selection. Nontransduced cells were used to determine the optimal concentration of antibiotic for selection.
Antibodies and reagents
Western blotting, immunoprecipitation, and immunofluorescence were performed using the following antibodies: an antibody recognizing the Pyo-derived epitope tag, which has been reported previously (110) ; antibodies recognizing MARK3 and vinculin (immunofluorescence) (Millipore); and antibodies against Flag (clone M2, Sigma) and HA (Covance). To detect endogenous ARHGEF2, we used a mouse monoclonal antibody (clone 3C5) designed using N-terminal human ARHGEF2 peptides and produced by hybridoma as previously described (26) and an antibody recognizing a region within amino acids 656 to 1000 of human ARHGEF2 (ab155785, Abcam). For endogenous immunoprecipitation of ARHGEF2, we used the ARHGEF2-specific antibody A301-929A (Bethyl); antibodies recognizing 14-3-3 (all isoforms), Myc (9E10), a-tubulin, and ZO-2 (immunofluorescence) (Santa Cruz Biotechnology); antibodies recognizing ERK1/2, pARHGEF2 Ser 
Expression constructs
Full-length, truncated, and mutated human ARHGEF2 constructs (NM_001162384.1) were cloned into the 3XFlag pCMV.10 vector (Sigma), pEGFP-C1 (Clontech), or pcDNA3.1/myc-His(−)B (Invitrogen) and verified by sequencing. Bovine DYNLT1 (accession no. NM_174620) and murine 14-3-3z (YWHAZ) were cloned into 3XFlag pCMV.10 or pGEX-4T-3 vectors for recombinant protein generation, as previously described (28) . pcDNA3 constructs encoding pyo-KSR1 N′424 (residues 1 to 424) and full-length pcDNA3-Pyo-MARK3
WT and pcDNA3-Pyo-MARK3 KD (kinase-deficient) have been previously described (40, 110) . In addition, full-length ARHGEF2 and MARK3 were cloned into the TREG vector (Clontech) and into pcDNA3 monomeric Cherry vectors. Point mutations were introduced by site-directed mutagenesis (QuikChange, Stratagene), and deletions were introduced by designing forward and reverse primers flanking the region to be deleted (Q5 Site-Directed Mutagenesis Kit, New England Biolabs Inc.).
For structural analyses of DYNLT1, a pGEX-4T-1 expression vector containing full-length murine DYNLT1 complementary DNA (cDNA) was a gift from M. Zhang (Hong Kong University of Science and Technology). Murine ARHGEF2 (AF177032) constructs [residues 136 to 161 and 136 to 164 and a variant of 136 to 161 with a cysteine substitution (Cys 136 )] were generated by annealing DNA oligomers with Bam HI and Eco RI compatible overhangs, which were ligated into a digested pGEX-4T-1 vector to encode thrombin-cleavable GST-fused fragments. A chimeric construct of ARHGEF2 residues 136 to 164 fused to the C terminus of DYNLT1 through a linker of sequence GLEGGSGGSG was generated by amplifying the ARHGEF2 region with primers encoding the additional linker sequence flanked by Xho I restriction sites. The TGA stop codon of DYNLT1 in the pGEX-4T-1 expression vector was mutated to GGA using QuikChange, and the vector and polymerase chain reaction (PCR) product were each digested by Xho I, ligated together, and screened for correct orientation by Sanger sequencing. The linker sequence was subsequently shortened to a single glycine using QuikChange.
Protein expression for structural analysis Escherichia coli BL21(DE3) CodonPlus-RIL (Agilent) cells were transformed with DYNLT1, DYNLT1:ARHGEF2 chimera, or murine ARHGEF2 constructs and grown overnight in lysogeny broth medium supplemented with chloramphenicol (50 mg/ml) and ampicillin (100 mg/ml) at 37°C while shaking. These cells were pelleted by centrifugation and transferred into fresh lysogeny broth for expression of unlabeled protein or M9 medium supplemented with [ Protein and peptide purification Frozen BL21 cell pellets expressing DYNLT1 or DYNLT1:ARHGEF2 chimera were thawed on ice and resuspended in lysis buffer [50 mM tris-HCl (pH 8.0), 300 mM NaCl, 0.5 mM EDTA (pH 8.0), 0.1% NP-40, and 2 mM DTT]. Cells were lysed by sonication, and the cell debris was removed by centrifugation. Glutathione Sepharose 4B resin (GE Healthcare Life Sciences) was mixed with the supernatant and incubated at 4°C for 1 hour. The resin was extensively washed with a high-salt buffer 1 [50 mM tris-HCl (pH 8.0), 300 mM NaCl, and 2 mM DTT] followed by a lower-salt buffer 2 [50 mM tris-HCl (pH 8.0), 150 mM NaCl, and 2 mM DTT]. The resin was resuspended, and DYNLT1 was cleaved from the GST tag by thrombin (10 U/mg of bound protein) for 48 hours at 4°C and then further purified on a Superdex 75 26/60 size exclusion column (GE Healthcare Life Sciences) run with 50 mM tris-HCl (pH 7.0), 400 mM KCl, and 2 mM DTT. Fractions containing pure DYNLT1 or DYNLT1:ARHGEF2 were collected and concentrated for NMR and crystallographic studies. ARHGEF2 peptides were purified in a similar manner using the following buffers: lysis buffer [50 mM trisHCl (pH 7.5), 150 mM NaCl, 10% glycerol, 10 mM b-mercaptoethanol, and 0.1% NP-40], wash buffer 1 [50 mM tris-HCl (pH 7.5), 500 mM NaCl, 10% glycerol, and 10 mM b-mercaptoethanol], and wash buffer 2 [50 mM tris-HCl (pH 7.5), 150 mM NaCl, 10% glycerol, and 10 mM b-mercaptoethanol], and size exclusion chromatography was performed using a Superdex Peptide 10/300 GL column (GE Healthcare Life Sciences) run with 50 mM tris-HCl (pH 7.0), 100 mM KCl, and 0.2 mM tris(2-carboxyethyl)phosphine (TCEP). Peptide concentrations were calculated by the absorbance at 214 nm using a JASCO spectrophotometer, and purity was determined by silver staining (Invitrogen) tris-tricine SDS-PAGE gels.
NMR spectroscopy 2D
1 H- 15 N HSQC spectra of 0.2 to 0.3 mM samples were acquired on Bruker Avance III 600-MHz and Bruker Avance II 800-MHz spectrometers at 25°C in a buffer consisting of 50 mM tris-HCl (pH 7.0), 100 mM KCl, 2 mM DTT, and 10% D 2 O. 3D spectra (HNCA, HNCOCA, CBCACONH, HNCACB, HNCO, HNCACO, and NOE spectroscopy) for backbone assignments of the DYNLT1:ARHGEF2 chimera were acquired on 0.3 mM samples at 800 MHz in 50 mM phosphate buffer (pH 6.7), 400 mM KCl, 2 mM DTT, and 10% D 2 O at 35°C. NMR data were processed with NMRDraw and NMRPipe (111), whereas spectra were analyzed with NMRView (82).
Paramagnetic relaxation enhancement ARHGEF2 peptides (residues 137 to 158) were synthesized with an additional cysteine at either the N terminus or C terminus (LifeTein) and a tryptophan at the opposite terminus to enable quantification by 280-nm ultraviolet absorption. Peptides were conjugated to a maleimide-linked EDTA tag (Toronto Research Chemicals) overnight at room temperature in the presence of 0. (112), and flash-frozen in liquid nitrogen. Diffraction and data collection were performed at the synchrotron x-ray source (Advanced Photon Source at Argonne National Laboratory), and phasing was solved by molecular replacement using the Drosophila DYNLT1 structure (PDB: 1YGT). Flexible portions of the structure were deleted, whereas nonconserved residues were modified to alanines. ). 14-3-3 protein was expressed as a recombinant GST fusion protein and purified by glutathione Sepharose followed by size exclusion chromatography. The affinity between these ARHGEF2 peptides and 14-3-3 protein was measured by MST (Monolith NT.115, NanoTemper) by preparing a series of standard MST glass capillaries containing each fluorescent peptide (100 nM) and increasing concentrations of GST-14-3-3 (serial dilutions from 195 mM to 2 nM) in 20 mM Hepes (pH 7.4), 150 mM NaCl, 1 mM DTT, and 0.05% Tween 20. Data were analyzed using the NanoTemper analysis software package. To investigate the effect of Ser 151 phosphorylation on binding of DYNLT1, a series of samples containing 10 nM ARHGEF2 peptides (residues 142 to 157 with and without Ser 151 phosphorylation) and increasing concentrations of GST-DYNLT1 (serial dilutions from 1.15 mM to 70 nM) were analyzed by fluorescence polarization using a Molecular Devices SpectraMax M5. Although K d values could not be determined because the binding curves did not reach saturation, phosphorylation had no appreciable effect on the binding curve.
MST and fluorescence polarization
BioID BioID (31) was performed as previously described (32) . In this assay, the promiscuous mutant biotin ligase BirA* (BirA
R118G
) is expressed as a fusion with the protein of interest such that it will biotinylate interacting and proximal proteins, which can then be identified by affinity purification and MS. Full-length human ARHGEF2 (NM_001162384.1) was amplified by PCR using specific primers (forward, 5′-GGCGCGCCAC-CATGTCTCGGATCGAATCCCTC-3′; reverse, 5′-AGT-TAGGCGGCCGCTTAGCTCTCGGAGGCTACAGC-3′) and cloned into the pcDNA5 FRT/TO FlagBirA* expression vector using Asc I and Not I restriction enzymes. Using the Flp-In system (Invitrogen), 293 FlpIn T-REx cells stably expressing FlagBirA* alone or the FlagBirA*-ARHGEF2 fusion were generated. After selection [DMEM + 10% FBS + hygromycin B (200 mg/ml)], subconfluent cells were incubated overnight in complete medium supplemented with tetracycline (1 mg/ml; Sigma) and 50 mM biotin (BioShop). Cells were collected and pelleted (2000 rpm for 3 min), and the pellets were washed twice with PBS, dried, and snap-frozen.
Biotin-streptavidin affinity purification for MS
The cell pellets were resuspended in 10 ml of lysis buffer [50 mM trisHCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 0.1% SDS, 1:500 protease inhibitor cocktail (Sigma-Aldrich), and 1:1000 TurboNuclease (Accelagen)] and incubated on an endover-end rotator at 4°C for 1 hour, briefly sonicated to disrupt any visible aggregates, and then centrifuged at 16,000g for 30 min at 4°C. The supernatant was transferred to a fresh 15-ml conical tube. Thirty microliters of packed, preequilibrated streptavidin Sepharose beads (GE Healthcare Life Sciences) was added, and the mixture was incubated for 3 hours at 4°C with end-over-end rotation. Beads were pelleted by centrifugation at 2000 rpm for 2 min and transferred with 1 ml of lysis buffer to a fresh Eppendorf tube. Beads were washed once with 1 ml of lysis buffer and twice with 1 ml of 50 mM ammonium bicarbonate (pH 8.3). Beads were transferred in ammonium bicarbonate to a fresh centrifuge tube and washed two more times with 1 ml of ammonium bicarbonate buffer. Tryptic digestion was performed by incubating the beads with 1 mg of MS-grade tosyl phenylalanyl chloromethyl ketone (TPCK)-treated trypsin (Promega) dissolved in 200 ml of 50 mM ammonium bicarbonate (pH 8.3) overnight at 37°C. The following morning, an additional 0.5 mg of trypsin was added and the beads were incubated for two additional hours at 37°C. Beads were pelleted by centrifugation at 2000g for 2 min, and the supernatant was transferred to a fresh Eppendorf tube. Beads were washed twice with 150 ml of 50 mM ammonium bicarbonate, and these washes were pooled with the first eluate. The sample was lyophilized and resuspended in buffer A (0.1% formic acid). Each MS analysis was performed on an aliquot of one-fifth of this sample.
Mass spectrometry MS was performed as previously described (34) . Briefly, analytical columns (inner diameter, 75 mm) and precolumns (inner diameter, 150 mm) were made in-house from fused silica capillary tubing (InnovaQuartz) and packed with 100 Å C 18 -coated silica particles (Magic, Michrom BioResources). Peptides were subjected to LC-electrospray ionization-MS/MS using a 120-min reversed-phase (100% water-100% acetonitrile, 0.1% formic acid) buffer gradient running at 250 nl/min on a Proxeon EASY-nLC pump in-line with a hybrid LTQ Orbitrap Velos mass spectrometer (Thermo Fisher Scientific). A parent ion scan was performed in the Orbitrap using a resolving power of 60,000, and then the most intense peaks (up to 20) were selected for MS/MS (minimum ion count of 1000 for activation) using standard collision-induced dissociation fragmentation.
Fragment ions were detected in the LTQ. A dynamic exclusion protocol was activated such that MS/MS spectra of the same m/z (mass/charge ratio) (within a range of 15 ppm; exclusion list size equal to 500) detected twice within 15 s were excluded from analysis for 30 s. For protein identification, Thermo.RAW files were converted to the .mzXML format using ProteoWizard (113) and then searched using X!Tandem (114) against the human (Human RefSeq Version 45) database. X!Tandem search parameters were as follows: parent mass error, 15 ppm; fragment mass error, 0.4 Da; complete modifications, none; cysteine modifications, none; and potential modifications, +16@M and W, +32@M and W, +42@N terminus, and +1@N and Q. Data were analyzed using the trans-proteomic pipeline (115, 116) via the ProHits software suite (117) . Proteins identified with a Protein Prophet cutoff of 0.9 and at least two unique peptides were analyzed with the SAINT (significance analysis of interactome) express algorithm (v3.3) (118) . Fourteen control runs (consisting of 14 FlagBirA* only) were collapsed to the three highest spectral counts for each prey. A Bayesian false discovery rate of 0.02 or higher, corresponding to a SAINT score of ≥0.79, was used to identify the bona fide interactors (119) . The interactions are from two independent biological replicates of FlagBirA*-ARHGEF2 (denoted as "A" and "B").
Isolation of MARK3 complexes and MS analysis
The experiment was performed as previously described (60) 
Immunofluorescence
For immunofluorescence imaging, subconfluent MDCKII cells were seeded on sterile Nunc Lab-Tek II chambered cover glass and treated the following day with doxycycline (10 to 500 ng/ml; Bio Basic Canada Inc.) or DMSO only as indicated for 18 to 24 hours. The cells were washed once with 1× PBS and visualized directly for live imaging or fixed with 4% paraformaldehyde at room temperature for 15 or 20 min for 3D culture cells. After fixation, the cells were washed three times with 1× PBS and permeabilized with 0.1% Triton X-100 for 10 to 15 min at room temperature, washed three times with 1× PBS, and blocked with 1× PBS, 1% bovine serum albumin (BSA), 0.1% Triton X-100, and 5% normal goat serum for 1 hour at room temperature. After blocking, the cover glass chambers were incubated at 4°C overnight with antibody specific for vinculin (Millipore) and diluted (1:300) in 1× PBS, 1% BSA, and 0.1% Triton X-100 at room temperature for 2 hours for 3D culture with an antibody against E-cadherin (1:1000; BD Biosciences). For the ZO-1, ZO-2, cleaved caspase 3 (diluted 1:100), and Ki67 (1:200) staining, the spheroids were permeabilized with 0.5% Triton X-100 for 15 min at room temperature, and the incubation with the primary antibody was done overnight at room temperature. After incubation with primary antibodies, the chambers were washed three times in 1× PBS and incubated with antibodies against mouse IgG (H+L) cross-adsorbed secondary antibody conjugated to Alexa Fluor 488, 568, or 647 (Invitrogen) and/or Alexa Fluor 647 phalloidin (1:50) for actin staining for 1 hour at room temperature. After incubation with the secondary antibody, the chambers were washed three times in 1× PBS, and if required, the nuclei were stained with DAPI (Molecular Probes, Invitrogen) for 10 min followed by two additional washes with 1× PBS. Confocal imaging was performed with an Olympus IX81 inverted microscope using a 60×/1.4 PlanApo oil or a 60×/1.20 water (Nikon) objectives.
Statistical analyses
Values are expressed as means, and error bars represent means ± SD. Statistical comparisons were made with Prism version 6.0e (GraphPad), and specific tests are indicated for each figure, where a statistical analysis was performed. All the tests were two-sided. A P value of ≤0.05 was considered statistically significant. Bonferroni adjustment was conducted to adjust for multiple comparisons for most of the tests.
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